X

Trial Profile

A trial of dalteparin low molecular weight heparin for primary prophylaxis of venous thromboembolism in brain tumour patients (PRODIGE).

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 12 Jun 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Dalteparin sodium (Primary)
Indications Thromboembolism
Focus Therapeutic Use
Acronyms PRODIGE

Most Recent Events

31 May 2020 Results of a pooled analysis from four phase III trials: CONKO-001, JASPAC-01, ESPAC-4 and PRODIGE assessing prolongation of average survival time, prolongation of average event free time and time lived without an event presented at the 56th Annual Meeting of the American Society of Clinical Oncology
22 Oct 2005 New trial record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com